Detailansicht

Wissensnetz

Person

Christina Eichstaedt

Molekularbiologin

Name	Christina Eichstaedt
Ort	Heidelberg (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Prof. Dr.
Beruf	Molekularbiologin (charakteristischer Beruf)
Variante	Christina A. Eichstaedt Christina Alessandra Eichstaedt C. A. Eichstaedt
Beziehung	Klinikum Heidelberg
Weitere Angaben	Molekularbiologin, Labor/Forschung, Phd of Biologigical Antrophology, Thoraxklinik, Universitätsklinikum Heidelberg
Datensatztyp	Person
GND-Nummer	1110189419
Datensatz-ID	1110189419
Beteiligt an alle anzeigen Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study Pulmonale Hypertonie bei Erwachsenen mit angeborenen Herzfehlern im Lichte der 2022-ESC-PAH-Leitlinien : Part II: Supportive Therapie, Sondersituationen (Schwangerschaft, Kontrazeption, nicht-kardiale Operationen), zielgerichtete Pharmakotherapie, Organtransplantation, spezielles Management (Shuntvitien, Linksherzerkrankungen, univentrikuläre Herzen), Interventionen, Intensivmedizin, Nachsorge, Zukunftsperspektive Hereditäre pulmonal-arterielle Hypertonie Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension Kommentar zu den Leitlinien (2022) der ESC/ERS zur Diagnostik und Behandlung der pulmonalen Hypertonie Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension Pulmonale arterielle Hypertonie bei Erwachsenen mit angeborenen Herzfehlern – Teil I Genetische Diagnostik und molekulare Ansätze bei pulmonalarterieller Hypertonie Genetische Grundlagen, Beratung und Testung bei Patienten mit pulmonalarterieller Hypertonie Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients? Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension Pulmonalarterielle Hypertonie bei Frauen Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension Effect of Supervised Training Therapy on Pulmonary Arterial Compliance and Stroke Volume in Severe Pulmonary Arterial Hypertension and Inoperable or Persistent Chronic Thromboembolic Pulmonary Hypertension Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study) EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension Pathobiologie, Pathologie und Genetik der pulmonalen Hypertonie: Empfehlungen der Kölner Konsensus-Konferenz 2016

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Christina Eichstaedt

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Hereditäre pulmonal-arterielle Hypertonie

Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

Kommentar zu den Leitlinien (2022) der ESC/ERS zur Diagnostik und Behandlung der pulmonalen Hypertonie

Safety and effectiveness of standardized exercise training in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (TRAIN-HFpEF-PH): study protocol for a randomized controlled multicenter trial

Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

Pulmonale arterielle Hypertonie bei Erwachsenen mit angeborenen Herzfehlern – Teil I

Genetische Diagnostik und molekulare Ansätze bei pulmonalarterieller Hypertonie

Genetische Grundlagen, Beratung und Testung bei Patienten mit pulmonalarterieller Hypertonie

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis

The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension

Pulmonalarterielle Hypertonie bei Frauen

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension

The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension

Effect of Supervised Training Therapy on Pulmonary Arterial Compliance and Stroke Volume in Severe Pulmonary Arterial Hypertension and Inoperable or Persistent Chronic Thromboembolic Pulmonary Hypertension

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension

Pathobiologie, Pathologie und Genetik der pulmonalen Hypertonie: Empfehlungen der Kölner Konsensus-Konferenz 2016